NXL Logo

Nexalin Technology, Inc. (NXL) 

NASDAQ
Market Cap
$47.85M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
363 of 945
Rank in Industry
43 of 120

Largest Insider Buys in Sector

NXL Insider Trading Activity

NXL Median Price and Trade Amounts History Chart

About Nexalin Technology, Inc.

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.

Insider Activity of Nexalin Technology, Inc.

Over the last 12 months, insiders at Nexalin Technology, Inc. have bought $27,674 and sold $0 worth of Nexalin Technology, Inc. stock.

On average, over the past 5 years, insiders at Nexalin Technology, Inc. have bought $27,674 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Owens David (Chief Medical Officer) — $27,674.

The last purchase of 2,000 shares for transaction amount of $6,080 was made by Owens David (Chief Medical Officer) on 2025‑02‑04.

List of Insider Buy and Sell Transactions, Nexalin Technology, Inc.

2025-02-04PurchaseChief Medical Officer
2,000
0.0154%
$3.04$6,080+12.38%
2025-02-04PurchaseChief Medical Officer
1,000
0.0076%
$2.98$2,980+12.38%
2025-01-28PurchaseChief Medical Officer
1,500
0.0126%
$2.70$4,050+21.21%
2025-01-23PurchaseChief Medical Officer
1,000
0.008%
$2.70$2,700+16.15%
2025-01-13PurchaseChief Medical Officer
2,000
0.0156%
$2.50$5,000+18.33%
2024-10-28PurchaseChief Medical Officer
500
0.0058%
$2.19$1,0950.00%
2024-08-13PurchaseChief Medical Officer
1,000
0.0097%
$0.95$9500.00%
2024-06-28PurchaseChief Medical Officer
1,000
0.0084%
$1.75$1,7500.00%
2024-06-18PurchaseChief Medical Officer
1,619
0.0056%
$0.71$1,149+119.23%
2024-06-10PurchaseChief Medical Officer
3,000
0.0093%
$0.64$1,920+124.24%

NXL Institutional Investors: Active Positions

Increased Positions16+94.12%397,332+199.03%
Decreased Positions7-41.18%80,661-40.41%
New Positions14New362,670New
Sold Out Positions5Sold Out75,794Sold Out
Total Postitions26+52.94%516,301+158.63%

NXL Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Renaissance Technologies Llc$300.000.79%102,900+102,900New2024-09-30
Geode Capital Management, Llc$230.000.61%78,697+34,635+78.61%2024-09-30
Citadel Advisors Llc$170.000.45%58,185+58,185New2024-09-30
Cvi Holdings, Llc$162.000.43%55,462+55,462New2024-06-30
Susquehanna International Group, Llp$124.000.33%42,383+42,383New2024-09-30
Vanguard Group Inc$93.000.24%31,78000%2024-09-30
Virtu Financial Llc$68.000.18%23,447+23,447New2024-09-30
Two Sigma Securities, Llc$67.000.18%23,045+23,045New2024-09-30
Drive Wealth Management, Llc$58.000.15%20,000+20,000New2024-12-31
Atria Wealth Solutions, Inc.$50.000.13%17,24200%2024-12-31
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.